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Cardiovascular  disease  is  the  leading  cause  of  morbidity  and  mortality  in  the world.  In  recent  years,  there
has  been  an  increasing  interest  both  in basic  and  clinical  research  regarding  the  ﬁeld of  cell  therapy
for  coronary  heart  disease  (CHD).  Several  preclinical  models  of  CHD  have  suggested  that  regenerative
properties  of  stem  and  progenitor  cells  might  help  restoring  myocardial  functions  in the  event  of  cardiac
diseases.  Here,  we  summarize  different  types  of stem/progenitor  cells  that have  been  tested  in  experi-
mental  and clinical  settings  of cardiac  regeneration,  from  embryonic  stem  cells to  induced  pluripotent
stem  cells.  Then,  we  provide  a comprehensive  description  of the most  common  cell  delivery  strategies
with  their  major  pros  and  cons and  underline  the potential  of  tissue  engineering  and  injectable  matri-
ces  to address  the crucial  issue  of  restoring  the three-dimensional  structure  of  the  injured  myocardial
region.  Due  to the encouraging  results  from  preclinical  models,  the  number  of  clinical  trials  with celllinical trials therapy  is continuously  increasing  and  includes  patients  with  CHD  and  congestive  heart  failure.  Most  of
the  already  published  trials  have  demonstrated  safety  and  feasibility  of  cell  therapies  in these  clinical
conditions.  Several  studies  have  also  suggested  that  cell  therapy  results  in improved  clinical  outcomes.
Numerous  ongoing  clinical  trials  utilizing  this  therapy  for CHD  will address  fundamental  issues  concern-
ing  cell  source  and  population  utilized,  as  well  as  the  use  of  imaging  techniques  to  assess  cell  homing
and  survival,  all factors  that  affect  the efﬁcacy  of  different  cell  therapy  strategies.©  2013  Japanese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
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ntroduction
Despite the fact that the incidence of cardiovascular disease
CVD) has dramatically declined over the past four decades, due to
he remarkable advances in the understanding of CVD pathophy-
iology and treatment, coronary heart disease (CHD), stroke, and
eripheral arterial disease (PAD) remain the leading causes of death
nd disability in Western countries [1]. In particular, myocardial
nfarction (MI) is associated with elevated mortality and morbid-
ty because it causes heart failure (HF) by inducing cardiomyocyte
CM) death and apoptosis. Until now, reducing the established risk
actors for CVD has worked successfully for both secondary and pri-
ary prevention. However, a novel and complementary approach,
hich could represent a major breakthrough in the ﬁeld, would
e the possibility to repair the damaged myocardium and/or blood
essels. This opportunity originates from the possibility of apply-
ng cell therapy to CVD and even more from the revolutionary
oncept that the human heart is not a post-mitotic organ, as tradi-
ionally believed, but an organ capable of regenerating its damaged
nd/or aged structures thanks to the activity of recently discovered
ndogenous or exogenous adult stem cells capable of improving
issue repair through regeneration of vessel and cardiac muscle
ells [2]. Indeed, a burst of regenerative activity was observed in
he heart of one-day-old mice after resection of the left ventricular
pex [3].
Recent attempts based on transplantation of adult stem and pro-
enitor cells to damaged areas of the cardiovascular system have
roduced interesting and promising results. However, to date there
s still the need to address some fundamental unresolved issues,
uch as identifying the optimal cell type, delivery strategy, thera-
eutic dose and timing, as well as determining the extent of cell
urvival and retention in the different settings. In this context,
urrent preclinical studies are aimed at ameliorating homing, cell
urvival, and retention and they are essentially based on genetic
odiﬁcations and the use of biomaterials for cell delivering. It is
rucial that ongoing and future clinical studies address these essen-
ial issues.
Here, we review the clinical aspects of different cell therapy
trategies in patients with CHD; we will also focus on the current,
oth completed and ongoing, clinical trials utilizing bone marrow
ells (BMCs) as source for cell therapy.
tem cell sources for cardiovascular regenerative therapy
Cell  therapy for CHD can be different according to the disease
rogression, but it is invariably expected to provide a renewable
ource of proliferating, functional CMs. However, stem cells are
are in humans: approximately, only 1 out of 10,000–100,000 BMCs
as been recognized as a hematopoietic stem cell, and only 1 out
f 30,000 cells in the heart has been identiﬁed as a c-kit-positive
ardiac stem cell (CSC) [4]. Cardiac niches have been identiﬁed
hat provide a harboring microenvironment to support and pro-
ect CSCs, as well as control their turnover and migration toward
ites of myocardial injury [4]. Interestingly, canine pulmonary veins
ave been shown to host cardiac stem cell niches [5]. . . . . .  . . .  . .  . . .  . .  . . .  . . . . .  . .  . . . . . . .  .  . . . . . . .  . . . . . .  .  . . . .  . . . . .  .  . . .  .  .  .  . . . . . . . . . .  273
In both preclinical and clinical studies, different types of cells
have been employed for cell therapy, mainly varying in regard to
their origin, expression of surface markers, function, and ability to
derive different cell types (Fig. 1a–d).
Embryonic stem cells
Embryonic  stem cells (ESCs), deriving from the embryo inner
mass at the blastocyst stage, would be the ideal stem cells. These
totipotent cells display the maximum potential for organ regener-
ation and can differentiate into a variety of cell types and tissues,
including CMs  and blood vessels, but they also increase the risk of
teratoma formation [6,7]. In several animal models ESC transplants
improved cardiac function [8] or blood perfusion [6,9]. Further-
more, genetically engineered human ESCs were able to electrically
pace quiescent, recipient ventricular CMs  in vitro and ventricular
myocardium in vivo [10]. The advantage of using ESCs derives from
their unlimited proliferative capacity and multilineage differentia-
tion plasticity, whereas the main disadvantages are the social and
ethical concerns due to the source and isolation methods. This eth-
ical matter, together with their potential genetic instability and
consequent risk of cancer development, renders these cells not
suitable for clinical application.
Fetal  stem cells
As  regard to cell source, fetal and human umbilical cord blood
cells should have more plasticity than adult stem cells even
though their pluripotency degree after in vitro expansion is still
unclear. These cells, comprising hematopoietic stem cells (HSCs),
mesenchymal stromal cells (MSCs), and somatic stem cells with
proliferative capacity, have showed promising results in animal
models, but no clinical studies were available until recently [11].
Adult  stem cells
Bone  marrow cells
Although  the ideal cell type for CHD cell therapy remains to
be determined, most clinical trials refer to the use of adult stem
cells from autologous bone marrow (BM) as the main source of
adult stem cells for cardiac regeneration. Despite the more limited
differentiation capacity, this choice can be explained by several
reasons, which include their easy availability and safety, the possi-
bility to expand and/or select them in vitro, the nonnecessity of an
immunosuppressive treatment, and the lack of ethical controver-
sies associated with the use of embryonic stem cells. Thus, most of
the published studies have utilized these cells (see Tables 1 and 2).
BM contains different cell subpopulations that have the poten-
tial to migrate to distant sites and differentiate into cells with
diverse phenotypes [12]. BMCs may  be isolated by direct aspira-
tion or by mobilization into the peripheral blood through the use
of cytokines such as granulocyte-colony stimulating factor (G-CSF)
[13,14]. The two  main groups of BM-derived stem cells are the HSCs
and the mesenchymal stem cells or MSCs, which can be further
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Fig. 1. (a–d) Stem cells and adult sources of multipotent cells for therapeutic intervention in coronary heart disease; embryonic stem cells (a), fetal and amniotic stem cells
(b),  adult multipotent stem cells (c), and induced pluripotent stem cells (d). (e–g) Cell delivery strategies used in cell therapy of heart diseases; intravenous injection (e),
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pntramyocardial injection (f), intracoronary injection (g). BMCs, bone marrow cells;
tem cells; SkMCs, skeletal muscle cells.
ubdivided into different subpopulations according to the expres-
ion of speciﬁc cell surface receptors.
The HSCs are usually identiﬁed by the expression of CD34, CD45,
nd/or CD133 antigens and have been widely studied and clinically
sed for a variety of disorders. A heterogeneous cell subpopulation
ncludes endothelial progenitor cells (EPCs), which are found also in
eripheral blood and fetal liver or umbilical cord blood. These cells
re deﬁned by the co-expression of the HSC markers CD34, CD45,
r CD133 and the vascular endothelial growth factor receptor-2
VEGFR2/KDR), although further cell populations expressing mono-
yte markers have been also identiﬁed [15,16]. Importantly, both
PC populations are known to directly or indirectly contribute to
ngiogenesis and promote neovascularization [15,16]. The use of
solated circulating EPCs, including G-CSF-mobilized BM progeni-
ors, has been extensively treated in a recent review [15] and it will
ot be the object of this paper.
The multipotent, non-hematopoietic MSCs originate from the
esoderm and the neuroectoderm and reside mainly in BM,
esides liver, white adipose tissue, intestine, lung, periodontal
igament, and dental pulp [17]. The isolation of highly puriﬁed
SCs is based on their surface antigen proﬁle; indeed, these cells
re positive for CD73, CD90, and CD105, and negative for CD34,
D45, CD14/CD11b, CD79/CD19, and HLA-DR antigens [17]. The
otential regenerative role is mainly based on experimental animal embryonic stem cells; iPSCs, induced pluripotent stem cells; MSCs, mesenchymal
studies since to date there are few published clinical studies with
isolated MSCs [17,18]. Indeed, in phase I clinical trials of acute MI,
MSC  therapy has been found to improve left ventricular function,
induce reverse remodeling, and decrease scar size, thus suggest-
ing their utilization in future clinical practice [17,18]. These cells
are present also in other adult tissues, such as adipose tissues, and
they can trans-differentiate into functional CMs  and a variety of
other cells [19–21]. Clinical trials are now ongoing to investigate
the safety, feasibility, and efﬁcacy of adult stem cells isolated from
adipose tissue in patients with both acute and chronic myocardial
ischemia.
In the end, a great deal of evidence documents that transplanted
BMCs reduce infarct size and improve left ventricular function and
perfusion in experimental animal models of acute MI  and ischemic
cardiomyopathy [22]. However, available human studies demon-
strate only a modest improvement in functional and structural
parameters in patients with both acute MI  and chronic ischemic
heart disease, compared to conventional state-of-the-art therapy
[23].Skeletal myoblasts
Further adult stem cells sources have been tested for their
therapeutic potential. For example, skeletal myoblasts have
been injected into the ischemic myocardium; however, neither
270 V. Grimaldi et al. / Journal of Cardiology 62 (2013) 267–276
Table 1
Published heart disease studies.
NIH registration number Study type No. of treated
patients
Cell  type Condition Delivery
route
Year [Ref]
NCT00114452 Randomized; controlled; blinded 39 MSCs MI  IV 2009 [18]
NCT00199823 Randomized; controlled 50 BMCs AMI  IC 2006 [44]; 2008 [45];
2009  [46]
NCT00264316 Randomized; controlled; blinded 33 BMCs AMI  IC 2006 [47]
NCT00289822 Randomized; controlled 28 BMCs MI  IC 2006 [48]
Unregistered Randomized; controlled 29 BMCs AMI  IC 2002 [49]; 2004 [50];
2011  [51]
Unregistered Randomized; controlled 30 BMCs MI  IC 2004 [52]; 2006 [53];
2009  [54]
NCT00279175 Randomized; controlled; multicenter 101 BMCs AMI  IC 2006 [55]; 2006 [56];
2010  [57]
Unregistered Randomized; controlled 24 BMCs NICM IC 2006 [58]
Unregistered Randomized; controlled 17 BMCs AMI  IC 2007 [59]
Unregistered Randomized; controlled; blinded 33 BMCs AMI  IC 2009 [60]
Unregistered Randomized; controlled 40 BMCs AMI  IC 2009 [61]
NCT00316381 Randomized; controlled; multicenter 80 CD34+ from BMCs AMI  IC 2009 [62]
NCT00284713 Randomized 33 BMCs NICM IC 2009 [63]
Unregistered Randomized; controlled 191 BMCs CIHD, HF IC 2010 [64]
NCT00235417 Non-randomized 32 BMCs CIHD, HF IC 2010 [65]
NCT00268307 Randomized; controlled; blinded 30 BMCs MI  IC 2010 [66]
NCT00313339 Randomized; controlled 16 BMCs STEMI IC 2011 [67]
NCT00669227 Randomized; controlled; blinded 29 BMCs AMI  IC 2010 [68]
NCT00400959 Randomized; controlled 15 CD133+ from BMCs STEMI IC 2011 [69]
NCT00395811 Randomized; controlled; blinded 31 BMCs MI  IC 2011 [70]
NCT00200707 Randomized; controlled; multicenter 52 BMCs AMI  IC 2011 [71]
NCT00684060 Randomized; controlled; blinded;
multicenter
58 BMCs MI  IC 2011 [72]
Unregistered Randomized; controlled 10 BMCs ICM, CHF IM 2005 [73]
Unregistered Randomized 10 SkMs MI  IM 2005 [26]
Unregistered Randomized; controlled 10 BMCs MI  IM 2006 [74]
Unregistered Randomized; controlled 12 SkMs MI  IM 2006 [28]
Unregistered Randomized; controlled 18 BMCs MI  IM 2006 [75]
Unregistered Randomized; controlled 20 CD133+ from BMCs CIHD IM 2007 [76]
Unregistered Randomized; controlled 18 BMCs IHF IM 2008 [77]
Unregistered Randomized; controlled 34 SkMs LVD, MI  IM 2008 [25]
Unregistered Randomized; controlled 25 BMCs ICM IM 2009 [78]
Unregistered Randomized; controlled 12 SkMs ICM IM 2009 [27]
Unregistered Randomized 12 MBCs CAD IM 2010 [79]
Unregistered Randomized 27 BMCs CAD TEC 2006 [80]
Unregistered Randomized 10 BMCs AMI, RA TEC 2006 [81]
Unregistered Non-randomized 10 BMCs MI  TEC 2007 [82]
Unregistered Randomized; controlled; blinded 19 BMCs CAD TEC 2007 [83]
Unregistered Randomized; controlled 50 BMCs MI  TEC 2009 [84]
NCT00203203 Randomized; controlled 20 BMCs HF TEC 2011 [85]
NCT00824005 Randomized; controlled; blinded 92 BMCs ICM, CIHD TEC 2012 [86]
AMI, acute myocardial infarction; BMCs, bone marrow cells; CAD, coronary artery disease; CHF, congestive heart failure; CIHD, chronic ischemic heart disease; HF, heart
failure; IC, intracoronary injection; ICM, ischemic cardiomyopathy; IHF, ischemic heart failure; IM,  intramyocardial injection; IV, intravenous injection; LVD, left ventricular
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lear evidence of transdifferentiation into CMs, nor improve-
ent in the patient outcome have been observed (see Table 1)
24–28]; recently, the use of “second generation” skeletal
yoblasts through cell enrichment methods has been hypothe-
ized [29]. On the other side of the coin, epicardial injection of
keletal myoblasts was associated with malignant arrhythmias
30].
esident cardiac stem cells
Resident  CSCs have been identiﬁed in the hearts of adult
umans and other mammalian species, thus revolutionizing the
ong-believed concept of the heart as a post-mitotic organ [4,31].
hese cells represent an autologous source of CSCs with the addi-
ional advantage of being tissue-speciﬁc and pre-committed to
he heart lineages. However, the limited number of resident CSCs
mposes their expansion before they can be used to achieve ther-
peutic goals. This has been accomplished by inducing in situ
roliferation of resident CSCs with appropriate stimuli. Despite
heir high proliferative potential, their capacity to repair extensiveic cardiomyopathy; NIH, National Institutes of Health; RA, refractory angina; SkMs,
ction.
b site http://clinicaltrials.gov/.
injury,  as in the case of acute MI,  is still uncertain [4,31]. Animal
studies using CSCs have demonstrated inconsistent beneﬁcial
effects [4,32]. However, initial results from a randomized phase
I trial suggest that intracoronary infusion of autologous CSCs is
effective in improving left ventricular (LV) systolic function and
reducing infarct size in patients with heart failure after MI, and
warrant further, larger, phase II studies [33]. Yet, recently, the
safety and efﬁcacy of intracoronary cardiosphere-derived cells in
regenerating infarcted myocardium has also been shown by the
CADACEUS trial, a randomized controlled prospective two-center
trial in subjects with LV dysfunction 2–3 months post-MI [34]. As
in most of these studies, also this trial did not include a placebo
control group because of the treatment invasiveness. Thus, further
studies with a larger number of treated subjects are required to
demonstrate the safety and efﬁcacy of these therapeutic strate-
gies.
Finally, it is important to recall that intramyocardial injection of
c-kit+ BMCs can induce endogenous progenitor-derived CMs  result-
ing in improved ventricular function in mice after MI  [35].
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Table  2
NIH  registered ongoing clinical studies with a number of heart disease patients > 50.
NIH registration number Status No. of treated patients Cell type Condition Delivery route Phase
NCT00877903 Active, not recruiting 220 MSCs AMI  IV II
NCT00326989 Unknown 100 BMCs CHF IC I and II
NCT00437710  Unknown 50 BMCs AMI  IC I and II
NCT01350310  Recruiting 60 BMCs HF IM II
NCT01267331 Recruiting 60 BMCs CMI, LVD IM I and II
NCT00711542  Recruiting 100 BMCs MI  IC I and II
NCT00790764  Active, not recruiting 60 BMCs HD, CAD IC vs TEC II
NCT00418418 Unknown 60 MSCs HF, MI,  CAD IM II
NCT00644410 Not yet recruiting 60 MSCs CHF IM I and II
NCT00936819  Not yet recruiting 100 EPCs from BMCs MI  IC II
NCT00462774 Completed 60 CD133+ from BMCs CAD, CHF, MI  IM II and III
NCT00950274  Recruiting 142 CD133+ from BMCs MI,  CAD IM III
NCT00810238 Active, not recruiting 240 BMCs HF TEC II and III
NCT00984178  Unknown 120 BMCs AMI  IC II
NCT00384982 Completed 116 BMCs MI  Percutaneous, IM and IC II
NCT01392105 Completed 80 MSCs AMI  IC II and III
NCT00691834  Not yet recruiting 50 BMCs AMI, HF IC II
NCT00908622 Recruiting 50 SkMs MI  Percutaneous implantation II
NCT00725738 Unknown 80 BMCs AMI  IC II and III
AMI, acute myocardial infarction; BMCs, bone marrow cells; CAD, coronary artery disease; CHF, congestive heart failure; CIHD, chronic ischemic heart disease; EPCs, endothelial
progenitor cells; HF, heart failure; IC, intracoronary injection; ICM, ischemic cardiomyopathy; IHF, ischemic heart failure; IM,  intramyocardial injection; IV, intravenous
injection; LVD, left ventricular dysfunction; MI,  myocardial infarction; MSCs, mesenchymal stem cells; NICM, nonischemic cardiomyopathy; NIH, National Institutes of
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nduced pluripotent stem cells
To overcome the ethical issue of ESCs, interest has focused
n induced pluripotent stem cells (iPSCs), which display ESC-like
roperties, but originate from adult somatic cells through nuclear
eprogramming by ectopic expression of stemness factors [36–38].
ovel and improved approaches of generating iPSCs by virus-free
ene delivery methods have been recently developed in order to
chieve patient-speciﬁc stem cells [39]. Another issue to be consid-
red is that iPSCs maintain the epigenetic memory of the cell type
rom which they derive. The clinical potential of these cells remains
o be determined, even though recent studies have demonstrated
hat human iPSCs can differentiate into functional myocytes [40].
hus, iPSCs may  represent a good promise in the ﬁeld of regenera-
ive medicine.
uture directions
pigenetic control of CM differentiation
Increasing evidence supports the role of epigenetic mechanisms
n regulating the switch between maintenance of stemness and lin-
age commitment, including the transition from cardiac progenitor
ells toward CMs  [41]. The recent discovery that a long noncoding
NA is crucial in the cardiovascular lineage commitment during
ammalian development highlights new avenues for the differen-
iation of novel CMs  [42]. It is predictable that in the near future
t will be possible to drive cardiac cell differentiation back and
orth by manipulating the epigenetic background of CMs  and their
recursors for regenerative purposes.
ibroblasts transdifferentiation into CMs
Both mouse embryonic ﬁbroblasts and postnatal cardiac or
ermal ﬁbroblasts have been successfully transdifferentiated into
unctional CMs, following forced expression of speciﬁc transcrip-
ion factors [43]. The possibility of reprogramming ﬁbroblasts into
ardiomyocytes directly within the infarct scar is on the horizon.ell  delivery strategies
A  safe, effective and feasible delivery system is essential for the
fﬁcacy of cardiovascular regenerative therapy. The objective ofnfarction; TEC, transendocardial injection.
b site http://clinicaltrials.gov/.
cell therapy, regardless of the cell source, is to repair the damaged
tissue by delivering the adequate cell number to the interested
area. The speciﬁc delivery technique should also elicit little or
no risk of hematogenous dissemination, since progenitor cells are
expected to cause metastatic tumor formation in the long-term.
For this reason, local administration methods should be favored
instead of systemic delivery methods. Moreover, optimal results
are achieved when cells are retained at the delivery site. Factors
inﬂuencing delivery include the microenvironment at the delivery
site, which is crucial for cell survival, maintenance, and/or hom-
ing.
Several cell delivery strategies are currently available for dif-
ferent cell types and target anatomical sites, ranging from direct
intramyocardial injection to intravascular, catheter-based, meth-
ods (Fig. 1e–g). However, as discussed below, none of them can
now be considered the preferred method.
The four major techniques used to deliver stem and progenitor
cells directly into the myocardium include: systemic intravenous
injection, intracoronary injection, and intramyocardial injection
(both direct epicardial injection and catheter-based transendocar-
dial injection) (Fig. 1e–g) (see Table 1) [18,25–28,44–85]. Variations
within each approach have been developed to solve issues of safety,
feasibility, cell viability, and retention. Moreover, further strate-
gies, such as intrapericardial delivery, are also under study [86].
The schedule of cell therapy related to the onset of disease is also
a crucial issue, especially for ischemic disease. The advantages
and disadvantages of the different strategies are brieﬂy discussed
below.
Intravenous delivery
The  intravenous delivery through a central venous catheter
would be the easiest and least invasive method, but cur-
rently, due to many disadvantages, it is not the method of
choice in clinical studies for heart diseases. Indeed, the efﬁ-
cacy of intravenous delivery of stem cells is mostly limited
because of the entrapment of the injected cells in the lungs
and other organs [87]. A clinical study of intravenous infu-
sion of BM-derived MSCs after MI  has shown the safety
of intravenous infusion of MSCs after 12-month follow-up
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nd preliminary data about the efﬁcacy of this therapy are available
18]. Presently, a phase II multicenter study is ongoing to evaluate
he safety and efﬁcacy of intravenous infusion following acute MI
NCT00877903).
ntracoronary delivery
Nowadays,  most studies are performed through percuta-
eous cell delivering, either by intracoronary or transendocardial
ethods, the safety of which has been clinically demonstrated
44–46,52–57,83–85]. In the intracoronary delivery approach, cells
re injected under pressure into a coronary artery through a bal-
oon catheter placed in the coronary artery, with the advantage that
he cells can be directly applied at the occlusion site, for example
fter an acute MI.  The pioneer clinical trial of intracoronary infusion
f mononuclear BMCs was performed on 20 patients and estab-
ished that such practice was safe and effective [49]. Thereafter,
OPCARE studies have demonstrated long-term safety after 5-year
ollow-up and suggested favorable effects on LV function [50,51].
oreover, additional recently published clinical trials (see Table 1)
ave conﬁrmed that intracoronary infusion is a safe strategy with a
odest cardiac function improvement [65–72]. Conversely, intra-
oronary transfer of autologous BMCs did not augment recovery
f global LV function in patients with timely reperfused MI,  but
t was found to favorably affect infarct remodeling in a random-
zed, double-blind, controlled study [47]. In the group of negative
tudies, the results of the ASTAMI trial indicate that intracoronary
MC treatment in acute MI  is safe in the long term, although only
 small improvement in exercise time was found in the treated
roup [46]. Moreover, other studies did not show positive effects
f intracoronary cell delivery in patients with MI  [68] or they found
everal complications [59], thereby suggesting that, despite the
asy applicability, this approach presents also some disadvantages.
owever, the study of Penicka had several limitations [59], such as
he small number of enrolled patients that also had poor LV func-
ion and late revascularization, thus suggesting that this subset of
atients could not beneﬁt from the autologous bone marrow cell
ransplantation. Differently, in the BOOST trial, although a sub-
tantial improvement in LV ejection fraction was observed at 6
onths [52], a subsequent analysis at 18 months [53], and a fur-
her evaluation at 5 years [55], have shown that a single dose of
MCs was not able to promote a sustained improvement in LV
ystolic function. Moreover, no signiﬁcant differences in mortality
nd other clinical endpoints between groups have been observed
t the longest follow-up [54]. However, this trial was  not pow-
red to assess clinical outcome; so these data can only support
he safety of the procedure, but not the possible effects on sub-
equent clinical events. More recently, the results of the rigorously
esigned LateTIME study have been published [72]. The novelty
f this trial was to investigate the use and therapeutic efﬁcacy of
ntracoronary autologous BMC  delivery 2–3 weeks following MI
hereas the majority of published trials have administered BMCs
ithin the ﬁrst week following primary percutaneous coronary
ntervention [72]. Finally, intracoronary administration of BMCs
mproved global LV-function and ameliorated adverse LV remod-
ling also during long-term follow up after MI  in the REPAIR-AMI
tudy [55–57,88].
Although there are few studies investigating non-ischemic
ardiomyopathies, pilot studies indicate that intracoronary BMC
mplantation can have potential clinical beneﬁts also in these
atients [58,63].Controlled Phase III clinical trials (NCT01392105,
CT00725738) are currently undergoing to evaluate the clin-
cal effects of intracoronary delivery of BMCs on cardiac function
see Table 2).iology 62 (2013) 267–276
Transendocardial delivery
The  transendocardial method allows direct cell delivery into the
target regions, also in patients with occluded arteries, and usually
involves the use of a customized injection catheter. Delivery can
also be facilitated by the guidance of electromechanical mapping
to identify with more precision suitable myocardial regions within
the ischemic area [89]. Alternatively, ﬂuoroscopic-based guidance
for cell delivery can be used to this aim. This approach can be
a good choice for patients with chronic heart disease, whereas
it may  be not appropriate for patients with acute MI  because of
the potential risk of endocardial damage or ventricular perforation
[89]. These observations have also been demonstrated in preclin-
ical studies [89]. Several clinical trials of transendocardial injection
have been published [79–85]. More recently, a randomized clini-
cal study of transendocardially-injected BMCs in severe coronary
artery diseases demonstrated that this strategy could improve car-
diac function [79].
Intramyocardial injection
Autologous  BMCs have been delivered intramyocardially dur-
ing surgical interventions, such as coronary artery bypass grafting
surgery in patients with chronic ischemic heart disease [76]. Sev-
eral clinical studies have suggested that direct myocardial cell
implantation can be an effective treatment for patients with chronic
ischemic HF [73,76,77,85]. Indeed, this approach provides a direct
route of cells delivery with good chance of cell engraftment in
the damaged area. A potential problem can be the increased num-
ber of early postoperative arrhythmic events, as shown in a study
combining myoblast injections with coronary surgery; however,
these events may  be also related to the cell type and/or disease
context [25]. Although cell therapy combined with surgical inter-
vention may  provide additional beneﬁts in the future, it is difﬁcult
to evaluate the overall effects of this clinical strategy. Another
catheter-based direct method using the coronary system, during
coronary artery bypass grafting, was shown to be safe and feasi-
ble in most patients; moreover, it was possible to reach otherwise
inaccessible areas of the cardiac apex [26]. This approach has dis-
played great potential in patients with ischemic heart disease even
though there are not additional studies supporting these promising
results.
Clinical studies comparing the different cell delivery techniques
are lacking. A small study compared intracoronary artery deliv-
ery with retrograde coronary venous approach in patients with
ischemic heart disease. This study demonstrated higher cell reten-
tion in ischemic myocardium when the intracoronary approach
was used, although the small sample size and the characteristics
of study design did not permit the authors to reach conclusions on
this important issue [90]. However, preclinical studies have shown
that intracoronary and transendocardial injection of BMCs resulted
in increased engraftment when compared with intravenous infu-
sion. Moreover, intracoronary delivery was more efﬁcient than
transendocardial delivery, but it was also associated with decreased
coronary blood ﬂow, thereby suggesting that local transendocardial
delivery may  be a preferable method for cell delivery [91].
Independently of the cell-delivering strategy utilized, the dif-
ferent outcomes observed in all the clinical studies with bone
marrow-derived progenitor cells may  be related to differences in
cell preparation protocols [92] as well as to imaging techniques for
ejection fraction evaluation by ventriculography, magnetic reso-
nance imaging, and echocardiography [23,92].The efﬁciency of delivery and retention is generally lower than
expected, and retention and survival of cells at target sites are
still inadequate. Indeed, a low rate of progenitor cell survival has
been found after injection of BMCs into the infarcted heart with
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ifferent delivery strategies, either by intracoronary delivery of
utologous BMC  transplantation [93] or direct myocardial injec-
ion in a preclinical rat model [94]. Moreover, the efﬁciency seems
o be independent of the cell type; for example, similar discourag-
ng results were also found for skeletal myoblasts implanted into
ouse hearts [95]. The cause of transplanted cell death is probably
elated to the nature of ischemic tissue and the presence of endoge-
ous factors, such as inﬂammatory molecules. Thus, approaches to
meliorate survival of delivered cells are still under investigation.
aracrine hypothesis
Human  studies of cell therapy in CHD have shown an overall
mprovement in cardiac and vascular function other than tissue
egeneration; however, in many cases the observed effects can-
ot be explained by the efﬁciency of stem and progenitor cell
elivery and engraftment. Thus, the alternative paracrine hypoth-
sis has been recently advanced and should be considered in the
valuation of the therapeutic efﬁcacy of all these studies. This
ypothesis establishes that the injected cells act in a paracrine
anner by releasing soluble factors into the surrounding tis-
ue, thus contributing to cardiac repair and regeneration. These
aracrine factors, such as cytokines, chemokines, and growth fac-
ors, are able to induce myocyte protection, CM cell cycle re-entry,
mproved cardiac metabolism, upregulation of angiogenesis and
eovascularization, and they may  mediate endogenous regenera-
ion through recruitment and activation of resident stem cells [96].
he demonstration and the whole understanding of these paracrine
echanisms can have many future clinical implications in the ﬁeld
f cell therapy for CHD. Indeed, the use of paracrine factors improv-
ng cardiovascular regeneration could be a safer treatment, due to
 lower risk of tissue disruption compared to direct cell injection.
inally, it has also been hypothesized that an ideal regenerative
herapy would employ a combination of both cells and paracrine
actors.
onclusions and future perspectives
Cell therapy for CHD has a great therapeutic potential. Several
linical trials, mainly phase I/II studies, have demonstrated the
afety and efﬁcacy of adult stem and progenitor cells in regener-
tive therapy of the cardiovascular system. However, some issues,
uch as cell source, dose, timing and delivery method, remain to be
ptimized, and various phase III clinical trials are now ongoing also
o address these points (see Table 2). As previously discussed, sev-
ral types of cell sources are now under investigation and include
ells derived from embryos (ESCs), fetal and umbilical cord blood
ells, as well as adult stem and progenitor cells isolated from bone
arrow, and also from other tissues such as adipose tissue, and,
nally, reprogrammed cells (iPSCs).
Despite major progress in cell delivery to the damaged heart,
etter cell engraftment and higher cell survival remain the major
roblems of current procedures especially for treatment of large
amaged areas and congenital heart defects. Another crucial point
or the efﬁcacy of cell therapy in restoring cardiovascular function is
he three-dimensional reorganization of cells in the injured region
nd the correct orientation of contracting elements.
Studies investigating the extent of cell homing and the long-
erm engraftment, using in vivo imaging techniques, revealed that
nly a low percentage of cells could be detected both in ani-
al models and in clinical trials; these ﬁndings suggested that better understanding of homing mechanisms might be crucial
or enhancing cell engraftment especially when cells are infused
ia the vascular route [97]. In turn, the poor engraftment causes
ither limited regeneration of cardiac tissue and/or blood vesselsiology 62 (2013) 267–276 273
and  also reduces the paracrine activity, which is known to signiﬁ-
cantly contribute to repair processes. Homing to damaged sites is a
complex process involving the interaction of several chemokines,
chemokine receptors, intracellular signaling, adhesion molecules
(selectins and integrins), and proteases [98]. Basically, two  strate-
gies might be used to enhance cell homing: cell pre-treatment to
activate incorporation or target tissue pre-treatment to provide
cytokines and chemo-attractant factors capable to stimulate cell
engraftment [97].
Novel  approaches aimed at improving cell survival are under
study and they include cell preconditioning [99], microencap-
sulation [100], and genetic modiﬁcation [101]. Also, alternative
strategies involving tissue engineering are now under investiga-
tion to ameliorate the efﬁcacy of cell therapy [89,102]. The leading
approaches consist of the use of injectable matrices as vehicles for
cell delivery; examples are given by collagen, engineered myocar-
dial patch made of viable and autologous tissue, matrigel with
ESC-derived CMs  alone and cultured with endothelial cells with or
without mouse embryonic ﬁbroblasts [89,102]. A different method
involves the utilization of the so-called “cell sheet engineering”
for myocardial regenerative therapy using temperature-responsive
culture dishes, which can be set with a single type of cells, such
as monolayered MSCs, myoblast or ESC-derived cardiac progeni-
tors, or as a composite cell culture, with CMs, endothelial cells, and
ﬁbroblasts [89,102].
Tissue  engineering can provide natural and/or synthetic matri-
ces favoring the survival, proliferation, and differentiation of the
implanted cells. Moreover, these scaffolds can drive the appropri-
ate cell alignment, supporting the restoration of the structural and
mechanical features of the native cardiac tissue.
Despite promising results in animal models, standard cell thera-
pies still have limited clinical applications. Probably, a great chance
for successful cell-based therapies in CVD could arise from the joint
effort of cell biology and tissue engineering.
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